Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 15/20 | 0.54 |
| ▸ | PPARA | Q07869 | 11/20 | 0.54 |
| ▸ | LIPC | P11150 | 1/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20472335 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL957682 | 0.94 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL954464 | 0.88 | HSD17B10 (0.66) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL12630099 | 0.86 | CFTR (0.57) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL953081 | 0.86 | PTGDR2 (0.55) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL20472219 | 0.85 | PTGDR2 (0.51) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL3784235 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL3062695 | 0.82 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL2924380 | 0.82 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL955308 | 0.81 | PTGDR2 (0.48) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101925575-B | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanillic acid receptor antagonist | AMOREPACIFIC CORP | 2014-06-18 | — | — | CN | disclosed |
| EP-2238105-B1 | NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS | AMOREPACIFIC CORP (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2014-01-09 | — | — | US | disclosed |
| US-8557872-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-01-20 | — | — | US | disclosed |
| CN-101925575-A | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist | AMOREPACIFIC CORP | 2010-12-22 | — | — | CN | disclosed |
| EP-2238105-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009096701-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | KDM4E 4650/4885ALDH1A1 787/4885HPGD 719/4885 |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | KDM4E 4650/4885ALDH1A1 787/4885HPGD 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.